¼¼°èÀÇ ÀüÀÚ Ã³¹æÀü ½ÃÀå
E-Prescribing
»óǰÄÚµå : 1757558
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 06¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 367 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,053,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,161,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

¼¼°èÀÇ ÀüÀÚ Ã³¹æÀü ½ÃÀåÀº 2030³â±îÁö 38¾ï ´Þ·¯¿¡ ´ÞÇÒ Àü¸Á

2024³â¿¡ 26¾ï ´Þ·¯·Î ÃßÁ¤µÇ´Â ¼¼°èÀÇ ÀüÀÚ Ã³¹æÀü ½ÃÀåÀº 2024-2030³â¿¡ CAGR 6.2%·Î ¼ºÀåÇϸç, 2030³â¿¡´Â 38¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ ¸®Æ÷Æ®¿¡¼­ ºÐ¼®ÇÑ ºÎ¹®ÀÇ ÇϳªÀÎ ¼Ö·ç¼Ç ÄÄÆ÷³ÍÆ®´Â CAGR 5.2%¸¦ ±â·ÏÇϸç, ºÐ¼® ±â°£ Á¾·á½Ã¿¡´Â 25¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ¼­ºñ½º ÄÄÆ÷³ÍÆ® ºÐ¾ßÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£ Áß CAGR 8.3%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 7¾ï 2,140¸¸ ´Þ·¯, Áß±¹Àº CAGR 9.5%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ ÀüÀÚ Ã³¹æÀü ½ÃÀåÀº 2024³â¿¡ 7¾ï 2,140¸¸ ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ÀÇ °æÁ¦´ë±¹ÀÎ Áß±¹Àº 2030³â±îÁö 7¾ï 6,700¸¸ ´Þ·¯ÀÇ ½ÃÀå ±Ô¸ð¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, ºÐ¼® ±â°£ÀÎ 2024-2030³âÀÇ CAGRÀº 9.5%ÀÔ´Ï´Ù. ±âŸ ÁÖ¸ñÇÒ ¸¸ÇÑ Áö¿ªº° ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖÀ¸¸ç, ºÐ¼® ±â°£ Áß CAGRÀº °¢°¢ 3.1%¿Í 5.9%·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR 4.0%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¼¼°èÀÇ ÀüÀÚ Ã³¹æÀü ½ÃÀå - ÁÖ¿ä µ¿Çâ°ú ÃËÁø¿äÀÎ Á¤¸®

±â¼úÀÌ Ã³¹æÀü °ü¸®ÀÇ ÇÙ½É ÀÎÇÁ¶ó¸¦ ¾î¶»°Ô º¯È­½Ãų °ÍÀΰ¡?

ÀüÀÚó¹æÀü ½Ã½ºÅÛÀÇ ÁøÈ­´Â ÀÇ·áÁø, ¾à±¹, ȯÀÚ °£ÀÇ °¡Àå Áß¿äÇÑ ¿¬°á°í¸® Áß Çϳª¸¦ µðÁöÅÐÈ­ÇÔÀ¸·Î½á Åõ¾à °ü¸® ȯ°æÀ» ÀçÆíÇϰí ÀÖ½À´Ï´Ù. ¾ÈÀüÇÏ°í »óÈ£ ¿î¿ë °¡´ÉÇÑ Ç÷§Æû¿¡ ±¸ÃàµÈ ÃֽŠÀüÀÚó¹æÀü ¼Ö·ç¼ÇÀº ÀÇ·áÁø¿¡¼­ ¾à±¹ ½Ã½ºÅÛÀ¸·Î Á÷Á¢ ó¹æÀüÀ» ÀüÀÚÀûÀ¸·Î Àü¼ÛÇÏ¿© ¼öÀÛ¾÷À¸·Î ÀÎÇÑ ½Ç¼ö¸¦ ÃÖ¼ÒÈ­Çϰí, ¿öÅ©Ç÷ο츦 °£¼ÒÈ­Çϸç, ÀǾàǰ 󹿰ú ȯÀÚÀÇ º¸Çè Ç÷£À» ½Ç½Ã°£À¸·Î ´ëÁ¶ÇÒ ¼ö ÀÖ°Ô ÇØÁÝ´Ï´Ù. Health Level Seven(HL7) ¹× FHIR(Fast Healthcare Interoperability Resources) Ç¥ÁØÀ» äÅÃÇÏ¿© ÀüÀÚó¹æÀü Åø¿Í ÀüÀڰǰ­±â·Ï(EHR)ÀÇ È£È¯¼ºÀ» ´õ¿í °­È­ÇÏ¿© Áø·á ³×Æ®¿öÅ© °£ ÀÓ»ó µ¥ÀÌÅ͸¦ ¿øÈ°ÇÏ°Ô ±³È¯ÇÒ ¼ö ÀÖµµ·Ï Áö¿øÇÕ´Ï´Ù. ¿øÈ°ÇÑ ÀÓ»ó µ¥ÀÌÅÍ ±³È¯ÀÌ °¡´ÉÇØÁ³½À´Ï´Ù.

ÀüÀÚó¹æÀü Ç÷§ÆûÀº ´Ü¼øÈ÷ »õ·Î¿î ó¹æÀüÀ» Àü¼ÛÇÏ´Â °Í¿¡¼­ ¹þ¾î³ª ºü¸£°Ô ±â´ÉÀ» È®ÀåÇϰí ÀÖ½À´Ï´Ù. ÷´Ü ½Ã½ºÅÛ¿¡´Â ÇöÀç ¾à¹°-¾à¹° »óÈ£ÀÛ¿ë °æ°í, ¾Ë·¹¸£±â °Ë»ç, º¹¿ë·® ±ÇÀå, ½Ç½Ã°£ ºÐ¼® ¹× ȯÀÚº° ¸Å°³º¯¼ö¸¦ ±â¹ÝÀ¸·Î ó¹æÀÚ¸¦ ¾È³»ÇÏ´Â ÀÓ»óÀû ÆÇ´Ü Áö¿ø(CDS) ÅøÀÌ ³»ÀåµÇ¾î ÀÖ½À´Ï´Ù. ¾à·Â µ¥ÀÌÅͺ£À̽º¿ÍÀÇ ÅëÇÕÀ» ÅëÇØ ÀÇ·áÁøÀº °ú°Å ó¹æ ³»¿ª, ¼øÀÀµµ ÆÐÅÏ, ±ÔÁ¦ ¾à¹° ÀÌ·ÂÀ» È®ÀÎÇÒ ¼ö ÀÖÀ¸¸ç, °úÀ× Ã³¹æÀÇ À§ÇèÀ» ÁÙÀÌ°í ¸¸¼ºÁúȯ °ü¸®¸¦ °­È­ÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀüÀÚ »çÀü ½ÂÀÎ(ePA) ¸ðµâÀ» žÀçÇÏ¿© Åõ¾à ½ÂÀÎÀ» ½Å¼ÓÇÏ°Ô Ã³¸®ÇÒ ¼ö ÀÖÀ¸¸ç, Ư¼ö ¾à¹°ÀÌ ÇÊ¿äÇÑ È¯ÀÚÀÇ Ä¡·á Áö¿¬À» ÁÙÀÏ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ±â¼úÀû ¾÷±×·¹À̵带 ÅëÇØ º´¿ø ³×Æ®¿öÅ©, ¿Ü·¡Áø·á¼¾ÅÍ, ¿ø°ÝÀÇ·á Ç÷§ÆûÀ¸·Î ºü¸£°Ô È®»êµÇ°í ÀÖ½À´Ï´Ù.

½ÃÀå È®´ë¸¦ ÃËÁøÇÏ´Â »õ·Î¿î ÀÌ¿ë »ç·Ê¿Í ÃÖÁ¾»ç¿ëÀÚ ¼±È£µµ´Â?

ÀüÀÚó¹æÀüÀÇ À¯¿ë¼ºÀº °¢±â ´Ù¸¥ ¿ä°Ç°ú ±ÔÁ¦ Àǹ«¸¦ °¡Áø ´Ù¾çÇÑ ÀÇ·á ¼­ºñ½º ºÐ¾ß¿¡¼­ ÀÎÁ¤¹Þ°í ÀÖ½À´Ï´Ù. 1Â÷ÀÇ·á ¹× ³»°ú¿¡¼­ ÀüÀÚó¹æÀüÀº Áý´Ü °Ç°­°ü¸® Àü·«ÀÇ Áß½ÉÀÌ µÇ°í ÀÖÀ¸¸ç, °³¾÷Àǰ¡ ´ë±Ô¸ð ȯÀÚ ÆÐ³ÎÀÇ Ä¡·á ¿ä¹ýÀ» Ç¥ÁØÈ­ÇÏ°í º¹¾à ¼øÀÀµµ¸¦ ¸ð´ÏÅ͸µÇÒ ¼ö ÀÖµµ·Ï µ½°í ÀÖ½À´Ï´Ù. Á¾¾çÇÐ, Á¤½Å°ú, ³»ºÐºñ³»°ú, ·ù¸¶Æ¼½º³»°ú µî Àü¹® Ŭ¸®´Ð¿¡¼­´Â º¹ÀâÇÑ ¾à¹° ¿ä¹ý, ¿ë·® Áõ·®, ´Ù¾àÁ¦ º´¿ë ¿ä¹ýÀ» Áö¿øÇÏ´Â ÀüÀÚ Ã³¹æ ÅøÀ» äÅÃÇϰí ÀÖ½À´Ï´Ù. ƯÈ÷ ÇൿÀÇÇÐ ÀÇ·á ¼­ºñ½º ÇÁ·Î¹ÙÀÌ´õµéÀº ±ÔÁ¦ ¾à¹°ÀÇ ÀüÀÚó¹æÀü(EPCS)À» Ȱ¿ëÇÏ¿© ¾ö°ÝÇÑ DEA ±ÔÁ¤À» ÁؼöÇϸ鼭 ¿öÅ©Ç÷ο츦 °£¼ÒÈ­Çϰí ÀÖ½À´Ï´Ù.

¿ø°ÝÀÇ·áÀÇ ºÎ»óÀº ÀüÀÚ Ã³¹æÀü µµÀÔÀÇ ÁÖ¿ä ÃËÁø¿äÀÎÀ¸·Î ºÎ»óÇϰí ÀÖÀ¸¸ç, ƯÈ÷ ÀÎÇÁ¶ó °ÝÂ÷ ¹× ÆÒµ¥¹Í °ü·Ã È¥¶õÀ¸·Î ÀÎÇØ ´ë¸é Áø·á°¡ °¨¼ÒÇϰí ÀÖ´Â Áö¿ª¿¡¼­ µÎµå·¯Áö°Ô ³ªÅ¸³ª°í ÀÖ½À´Ï´Ù. ¿ø°ÝÀÇ·á ÇÁ·Î¹ÙÀÌ´õµéÀº ÇöÀç °¡»ó Áø·á Ç÷§Æû°ú ¸ð¹ÙÀÏ ¾ÖÇø®ÄÉÀ̼ǿ¡ ÅëÇÕÇÒ ¼ö ÀÖ´Â ÀüÀÚ Ã³¹æÀü ±â´ÉÀ» ¿ä±¸Çϰí ÀÖ½À´Ï´Ù. ¼ÒºñÀÚ Çൿµµ º¯È­Çϰí ÀÖÀ¸¸ç, ȯÀÚµéÀº ó¹æÀüÀÌ Áö¿¬À̳ª Á¾ÀÌ ±â¹ÝÀÇ Áߺ¹¼º ¾øÀÌ ¿øÇÏ´Â ¾à±¹À¸·Î Á÷Á¢ Àü´ÞµÇ±â¸¦ Á¡Á¡ ´õ ¸¹ÀÌ ±â´ëÇϰí ÀÖ½À´Ï´Ù. ÇÑÆí, ¾à±¹Àº ÀüÀÚó¹æÀüÀÇ ½Ç½Ã°£ 󸮸¦ Áö¿øÇϰí, º¸Çè Áø·áÀÇ º»Àκδã±Ý°ú ¾àǰÀÇ ´ëüǰ¿¡ ´ëÇÑ °¡½Ã¼ºÀ» È®º¸ÇÏ´Â ½Ã½ºÅÛ¿¡ ÅõÀÚÇϰí ÀÖ½À´Ï´Ù. ¼Ò¸Å ¾à±¹ üÀÎ, Åë½ÅÆÇ¸Å ¼­ºñ½º, Àü¹® ÀǾàǰ ÆÇ¸Å ȸ»ç´Â µðÁöÅРó¹æ »ýŰ迡¼­ Áß¿äÇÑ ÀÌÇØ°ü°èÀÚ°¡ µÇ°í ÀÖ½À´Ï´Ù.

ÄÄÇöóÀ̾𽺠Àǹ«È­¿Í ±ÔÁ¦ °³ÇõÀº ¾î¶»°Ô µµÀÔ °æ·Î¸¦ Çü¼ºÇϰí Àִ°¡?

Á¤ºÎÀÇ Àǹ«È­ ¹× ±ÔÁ¦ °³ÇõÀº ÀüÀÚó¹æÀü Ç÷§ÆûÀÇ ¼ºÀå ±Ëµµ¸¦ Çü¼ºÇÏ´Â µ¥ °áÁ¤ÀûÀÎ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù. ¹Ì±¹¿¡¼­´Â Medicare Prescription Drug, Improvement, and Modernization Act¿Í SUPPORT for Patients and Communities Act¿¡ µû¶ó Medicare Part D ÀǾàǰÀÇ ±ÔÁ¦ ÀǾàǰ ÀüÀÚó¹æÀü(EPCS)ÀÌ Àǹ«È­µÇ¾ú½À´Ï´Ù. EPCS)°¡ Àǹ«È­µÇ¾î ÀÖ½À´Ï´Ù. °¢ ÁÖ¿¡¼­µµ À¯»çÇÑ Àǹ«¸¦ äÅÃÇÏ¿© ÀÇ·á ¼­ºñ½º ÇÁ·Î¹ÙÀÌ´õ ¹× ÀÇ·á ½Ã½ºÅÛ¿¡ EPCS ȣȯ ÀÎÁõ ±â¼úÀ» µµÀÔÇϵµ·Ï Àå·ÁÇϰí ÀÖ½À´Ï´Ù. À¯·´¿¬ÇÕ(EU)¿¡¼­´Â À¯·´ ÀÇ·á µ¥ÀÌÅÍ °ø°£(EHDS) ¹× e-Çコ ³×Æ®¿öÅ© °¡À̵å¶óÀο¡ ±â¹ÝÇÑ µðÁöÅÐ Çコ ÁöħÀÌ ±¹°¡ °£ ó¹æÀü 󸮸¦ À§ÇØ °¢±¹ÀÇ ÀüÀÚ Ã³¹æÀü ½Ã½ºÅÛ °£ÀÇ »óÈ£ ¿î¿ë¼ºÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù.

¹Ì±¹ÀÇ HIPAA³ª À¯·´ÀÇ GDPR(EU °³ÀÎÁ¤º¸º¸È£±ÔÁ¤)°ú °°Àº ÇÁ¶óÀ̹ö½Ã ¹× µ¥ÀÌÅÍ º¸¾È ±ÔÁ¦´Â ¾ÈÀüÇÑ Àü¼Û, ¾×¼¼½º Á¦¾î, °¨»ç ·Î±×, ȯÀÚ µ¿ÀÇ ¸ÞÄ¿´ÏÁòÀ» º¸ÀåÇϱâ À§ÇØ ÀüÀÚó¹æÀü ½Ã½ºÅÛÀÇ ¾ÆÅ°ÅØÃ³¿¡ ¿µÇâÀ» ¹ÌÄ¡°í ÀÖ½À´Ï´Ù. µ¿½Ã¿¡ Àü ¼¼°è ÀǾàǰ ¾ÈÀü ´ç±¹Àº ¾à¹°°¨½Ã ¹× ó¹æ¾à ¸ð´ÏÅ͸µ ÇÁ·Î±×·¥(PDMP)¿¡¼­ ÀüÀÚ Ã³¹æÀüÀÇ ¿ªÇÒÀ» °­Á¶Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ½Ã½ºÅÛ¿¡´Â Áߺ¹ Ä¡·á, ´Ù¾àÁ¦ º¹¿ë À§Çè, Ãë¾à °èÃþÀÇ °íÀ§Çè ¾à¹° Á¶ÇÕÀ» Ç¥½ÃÇÏ´Â ÃßÀû ±â´ÉÀÌ ³»ÀåµÇ¾î ÀÖ½À´Ï´Ù. ¹Ì±¹ÀÇ MU(Meaningful Use) ¹× MIPS(Merit-Based Incentive Payment System)¿Í °°Àº ±ÔÁ¦Àû Àμ¾Æ¼ºê´Â ÀÇ·á ¼­ºñ½º ÇÁ·Î¹ÙÀÌ´õ°¡ ÀüÀÚó¹æÀü ±â´ÉÀ» äÅÃÇϰí ÃÖÀûÈ­ÇÒ ¼ö ÀÖ´Â °æÁ¦Àû µ¿±â¸¦ Áö¼ÓÀûÀ¸·Î Á¦°øÇÕ´Ï´Ù.

¼¼°è ÀüÀÚó¹æÀü ½ÃÀåÀÇ ±Þ°ÝÇÑ ¼ºÀåÀ» À̲ô´Â ¿äÀÎÀº ¹«¾ùÀΰ¡?

ÀüÀÚó¹æÀü ½ÃÀåÀÇ ¼ºÀåÀº Çö´ë ÀÇ·á ¼­ºñ½º Á¦°ø¿¡¼­ ÀüÀÚó¹æÀüÀÇ Á߿伺À» Áö¿øÇÏ´Â ¸î °¡Áö ¿äÀο¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù. °¡Àå °­·ÂÇÑ ¿øµ¿·Â Áß Çϳª´Â Åõ¾àÀÇ Á¤È®¼º°ú ȯÀÚ ¾ÈÀü¿¡ ´ëÇÑ ¿ä±¸°¡ Áõ°¡Çϰí ÀÖ´Ù´Â Á¡ÀÔ´Ï´Ù. °í·ÉÈ­ »çȸ¿Í ¸¸¼ºÁúȯ °ü¸®°¡ °­È­µÇ´Â °¡¿îµ¥, ó¹æ ¿À·ù¸¦ ÁÙÀ̰í ÀÓ»óÀû ¸ð´ÏÅ͸µÀ» °¡´ÉÇÏ°Ô ÇÏ´Â µðÁöÅÐ Ç÷§ÆûÀÇ Çʿ伺ÀÌ Áß¿äÇØÁö°í ÀÖ½À´Ï´Ù. »ý¹°Á¦Á¦, ¹ÙÀÌ¿À½Ã¹Ð·¯, Ư¼ö ÀǾàǰÀ» Æ÷ÇÔÇÑ ÀǾàǰ ó¹æÀÌ º¹ÀâÇØÁü¿¡ µû¶ó Àû¿ë ¹üÀ§ È®ÀÎ, ±Ý±â »çÇ× Ç÷¡±× ¼³Á¤, Àçó¹æ Áֱ⠰ü¸®°¡ °¡´ÉÇÑ µ¿Àû ½Ã½ºÅÛÀÇ Çʿ伺ÀÌ ³ô¾ÆÁö°í ÀÖ½À´Ï´Ù.

¶Ç ´Ù¸¥ Å« ¿øµ¿·ÂÀº µðÁöÅÐÈ­µÈ °¡Ä¡ ±â¹Ý Áø·á ¸ðµ¨·ÎÀÇ ±¸Á¶Àû ÀüȯÀÔ´Ï´Ù. ÀÇ·á ½Ã½ºÅÛÀº ȯÀÚ °á°ú¸¦ °³¼±Çϰí, ÀçÀÔ¿øÀ» ÁÙÀ̸ç, ǰÁú ÁöÇ¥¸¦ ÀÔÁõÇØ¾ß ÇÒ Çʿ伺ÀÌ ÀÖ½À´Ï´Ù. ÀüÀÚó¹æÀü ÅøÀº Åð¿ø½Ã º¹¾à Á¶Á¤À» °¡´ÉÇÏ°Ô Çϰí, ¸®ÇÊ ¸®¸¶Àδõ¸¦ ÀÚµ¿È­Çϸç, Áý´Ü °Ç°­ ºÐ¼®°ú ÅëÇÕÇÏ¿© ¾à¹° ¼øÀÀµµ°¡ ³·Àº ȯÀÚ¸¦ ½Äº°ÇÏ´Â µî ÀÌ·¯ÇÑ º¯È­¿¡¼­ Áß¿äÇÑ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ ÀüÀÚó¹æÀüÀÌ ¿ø°Ý ȯÀÚ ¸ð´ÏÅ͸µ, °¡»ó ¾à±¹ »ó´ã, ȯÀÚ Æ÷Åаú °°Àº ±¤¹üÀ§ÇÑ µðÁöÅÐ Çコ Ç÷§Æû°ú ÅëÇյǸ鼭, º¹¾à °ü¸®°¡ ´õ ÀÌ»ó »çÀÏ·ÎÈ­µÇÁö ¾Ê°í Á¾´ÜÀû Ä¡·á °æ·Î¿¡ ¿øÈ°ÇÏ°Ô ÅëÇÕµÈ ÅëÇÕµÈ ¿¡ÄڽýºÅÛÀÌ ±¸ÃàµÇ°í ÀÖ½À´Ï´Ù. ±¸ÃàµÇ°í ÀÖ½À´Ï´Ù.

½ÅÈï ½ÃÀå¿¡¼­ÀÇ ÇコÄɾî ÀÎÇÁ¶ó È®ÀåÀº ÀüÀÚó¹æÀü »ê¾÷¿¡ »õ·Î¿î ÁöÆòÀ» ¿­°í ÀÖ½À´Ï´Ù. ¾Æ½Ã¾ÆÅÂÆò¾ç, ¶óƾ¾Æ¸Þ¸®Ä«, Áßµ¿ ±¹°¡µéÀº ±¹°¡ º¸°Ç Àü·«°ú ¹Î°ü ÆÄÆ®³Ê½ÊÀ» ÅëÇØ ÇコÄÉ¾î ½Ã½ºÅÛÀ» µðÁöÅÐÈ­Çϰí ÀÖÀ¸¸ç, ÀüÀÚó¹æÀü µµÀÔ¿¡ ÀûÇÕÇÑ È¯°æÀ» Á¶¼ºÇϰí ÀÖ½À´Ï´Ù. Ŭ¶ó¿ìµå ³×ÀÌÆ¼ºê, ¸ð¹ÙÀÏ ¿ì¼±ÀÇ Ã³¹æ ÅøÀº ¿ÀÇÁ¶óÀÎ ±â´É, ´Ù±¹¾î ÀÎÅÍÆäÀ̽º, Áö¿ª ÀÇ·á ³×Æ®¿öÅ©¿ÍÀÇ ÅëÇÕ µî ÀÌ·¯ÇÑ È¯°æ¿¡ ´ëÀÀÇÒ ¼ö ÀÖµµ·Ï ¼³°èµÇ¾î ÀÖ½À´Ï´Ù. Á¦¾à»ç, ÀǷẸÇè»ç, PBM(Pharmacy Benefit Manager)ÀÌ µðÁöÅÐ ÀüȯÀ» ¿ì¼±¼øÀ§¿¡ µÎ°í ÀÖ´Â °¡¿îµ¥, ÀüÀÚó¹æÀü ½ÃÀåÀº Áö¼ÓÀû ÀÌ°í ¼¼°èÇÏ°Ô ¼ºÀåÇϰí ÀÖÀ¸¸ç, Çõ½ÅÀº ÄÄÇöóÀ̾𽺸¦ ³Ñ¾î ¾÷¹« È¿À²¼º, ÀÓ»ó ÀÎÅÚ¸®Àü½º, °³ÀÎÈ­µÈ Åõ¾à °ü¸®, °³ÀÎÈ­µÈ °³ÀÎÈ­µÈ Åõ¾à °ü¸®¸¦ ½ÇÇöÇÕ´Ï´Ù.

ºÎ¹®

ÄÄÆ÷³ÍÆ®(¼Ö·ç¼Ç ÄÄÆ÷³ÍÆ®, ¼­ºñ½º ÄÄÆ÷³ÍÆ®); Àü¹® ºÐ¾ß(Á¾¾çÇÐ Àü¹® ºÐ¾ß, ½ºÆ÷Ã÷ ÀÇÇÐ Àü¹® ºÐ¾ß, ½Å°æÇÐ Àü¹® ºÐ¾ß, ¼øÈ¯±âÇÐ Àü¹® ºÐ¾ß, ±âŸ Àü¹® ºÐ¾ß); µô¸®¹ö¸® ¸ðµå(Web/Ŭ¶ó¿ìµå ±â¹Ý µô¸®¹ö¸® ¸ðµå, ¿ÂÇÁ·¹¹Ì½º µô¸®¹ö¸® ¸ðµå)

Á¶»ç ´ë»ó ±â¾÷ÀÇ ¿¹(ÃÑ 34°Ç)

AI ÅëÇÕ

¿ì¸®´Â À¯È¿ÇÑ Àü¹®°¡ ÄÁÅÙÃ÷¿Í AI Åø¿¡ ÀÇÇØ ½ÃÀå Á¤º¸¿Í °æÀï Á¤º¸¸¦ º¯ÇõÇÕ´Ï´Ù.

Global Industry Analysts´Â ÀϹÝÀûÀÎ LLM³ª ¾÷°èº° SLM Äõ¸®¿¡ µû¸£´Â ´ë½Å¿¡, ºñµð¿À ±â·Ï, ºí·Î±×, °Ë»ö ¿£Áø Á¶»ç, ´ë·® ±â¾÷, Á¦Ç°/¼­ºñ½º, ½ÃÀå µ¥ÀÌÅÍ µî, Àü ¼¼°è Àü¹®°¡·ÎºÎÅÍ ¼öÁýÇÑ ÄÁÅÙÃ÷ ¸®Æ÷ÁöÅ丮¸¦ ±¸ÃàÇß½À´Ï´Ù.

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»çÀÇ ±¹°¡, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±â¹ÝÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇß½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ¼öÀÔ¿ø°¡(COGS) Áõ°¡, ¼öÀͼº °¨¼Ò, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû ¹× °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå °³¿ä

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

KSA
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global E-Prescribing Market to Reach US$3.8 Billion by 2030

The global market for E-Prescribing estimated at US$2.6 Billion in the year 2024, is expected to reach US$3.8 Billion by 2030, growing at a CAGR of 6.2% over the analysis period 2024-2030. Solutions Component, one of the segments analyzed in the report, is expected to record a 5.2% CAGR and reach US$2.5 Billion by the end of the analysis period. Growth in the Services Component segment is estimated at 8.3% CAGR over the analysis period.

The U.S. Market is Estimated at US$721.4 Million While China is Forecast to Grow at 9.5% CAGR

The E-Prescribing market in the U.S. is estimated at US$721.4 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$767.0 Million by the year 2030 trailing a CAGR of 9.5% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.1% and 5.9% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.0% CAGR.

Global E-Prescribing Market - Key Trends & Drivers Summarized

How Is Technology Transforming the Core Infrastructure of Prescription Management?

The evolution of e-prescribing systems has reshaped the landscape of medication management by digitizing one of the most critical links between providers, pharmacies, and patients. Built on secure, interoperable platforms, modern e-prescribing solutions facilitate the electronic transmission of prescriptions from healthcare providers directly to pharmacy systems, minimizing manual errors, streamlining workflows, and enabling real-time validation against drug formularies and patient insurance plans. The adoption of Health Level Seven (HL7) and Fast Healthcare Interoperability Resources (FHIR) standards has further enhanced the compatibility of e-prescription tools with Electronic Health Records (EHRs), ensuring seamless exchange of clinical data across care networks.

E-prescribing platforms are rapidly expanding in functionality beyond the basic transmission of new prescriptions. Advanced systems now incorporate drug-drug interaction alerts, allergy checks, dosing recommendations, and clinical decision support (CDS) tools that guide prescribers based on real-time analytics and patient-specific parameters. Integration with medication history databases allows providers to review prior prescriptions, adherence patterns, and controlled substance histories-reducing risks of overprescription and enhancing chronic disease management. The inclusion of electronic prior authorization (ePA) modules enables faster processing of medication approvals, reducing treatment delays for patients requiring specialty drugs. These technological upgrades are driving rapid deployment across hospital networks, ambulatory care centers, and telehealth platforms.

What Are the Emerging Use Cases and End-User Preferences Driving Market Expansion?

The utility of e-prescribing is being recognized across a growing array of healthcare delivery settings, each with distinct requirements and regulatory obligations. In primary care and internal medicine, e-prescribing is becoming central to population health management strategies, enabling practitioners to standardize treatment regimens and monitor medication adherence across large patient panels. Specialty clinics in oncology, psychiatry, endocrinology, and rheumatology are adopting e-prescribing tools that support complex medication regimens, dosage titrations, and multi-drug therapies. Behavioral health providers, in particular, are leveraging electronic prescribing for controlled substances (EPCS) to streamline workflows while complying with tight DEA regulations.

The rise of telemedicine has emerged as a major accelerant for e-prescribing adoption, particularly in regions where in-person visits have declined due to infrastructure gaps or pandemic-related disruptions. Telehealth providers now demand e-prescribing capabilities that can be embedded into virtual consultation platforms and mobile applications. Consumer behavior is also evolving, with patients increasingly expecting their prescriptions to be sent directly to their preferred pharmacies without delays or paper-based redundancies. Pharmacies, in turn, are investing in systems that support real-time processing of electronic prescriptions and offer visibility into insurance copay structures and medication substitutions. Retail pharmacy chains, mail-order services, and specialty drug distributors are becoming key stakeholders in the digital prescribing ecosystem.

How Are Compliance Mandates and Regulatory Shifts Shaping Adoption Pathways?

Government mandates and regulatory reforms are playing a defining role in shaping the growth trajectory of e-prescribing platforms. In the United States, mandates under the Medicare Prescription Drug, Improvement, and Modernization Act, as well as the SUPPORT for Patients and Communities Act, require the electronic prescribing of controlled substances (EPCS) for Medicare Part D drugs. Similar mandates have been adopted across individual states, prompting healthcare providers and health systems to implement certified EPCS-compliant technologies. In the European Union, digital health directives under the European Health Data Space (EHDS) and eHealth Network guidelines are encouraging interoperability between national e-prescribing systems, particularly for cross-border prescription fulfillment.

Privacy and data security regulations, such as HIPAA in the U.S. and GDPR in Europe, are influencing the architecture of e-prescribing systems to ensure secure transmission, access control, audit logging, and patient consent mechanisms. At the same time, global drug safety authorities are emphasizing the role of e-prescribing in pharmacovigilance and prescription drug monitoring programs (PDMPs). These systems are being embedded with tracking functionalities that flag duplicate therapies, polypharmacy risks, and high-risk medication combinations in vulnerable populations. Regulatory incentives, including Meaningful Use (MU) and Merit-Based Incentive Payment System (MIPS) in the U.S., continue to provide financial motivation for providers to adopt and optimize e-prescribing capabilities.

What Forces Are Fueling the Rapid Growth of the Global E-Prescribing Market?

The growth in the e-prescribing market is driven by several factors that collectively underscore its rising centrality in modern healthcare delivery. One of the most powerful drivers is the increasing demand for medication accuracy and patient safety. As polypharmacy becomes more prevalent among aging populations and chronic disease management intensifies, the need for digital platforms that can reduce prescription errors and enable clinical oversight is becoming critical. The growing complexity of pharmaceutical formularies, including biologics, biosimilars, and specialty drugs, has heightened the need for dynamic systems that can validate coverage, flag contraindications, and manage refill cycles.

Another major driver is the structural shift toward digitized, value-based care models. Health systems are under pressure to improve patient outcomes, reduce readmissions, and demonstrate quality metrics. E-prescribing tools are playing an instrumental role in this shift by enabling medication reconciliation at discharge, automating reminders for refills, and integrating with population health analytics to identify patients at risk for non-adherence. Additionally, the convergence of e-prescribing with broader digital health platforms-such as remote patient monitoring, virtual pharmacy counseling, and patient portals-is creating a cohesive ecosystem where medication management is no longer siloed but seamlessly integrated into longitudinal care pathways.

The expansion of healthcare infrastructure in emerging markets is further opening new frontiers for the e-prescribing industry. Countries in Asia-Pacific, Latin America, and the Middle East are increasingly digitizing healthcare systems under national health strategies and public-private partnerships, creating fertile ground for e-prescribing deployment. Cloud-native, mobile-first prescribing tools are being designed to accommodate these settings, with offline functionality, multi-language interfaces, and integration with community health networks. As pharmaceutical companies, health insurers, and pharmacy benefit managers (PBMs) continue to prioritize digital transformation, the e-prescribing market is poised for sustained and global growth, with innovation extending beyond compliance to deliver operational efficiency, clinical intelligence, and personalized medication management.

SCOPE OF STUDY:

The report analyzes the E-Prescribing market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Component (Solutions Component, Services Component); Specialty (Oncology Specialty, Sports Medicine Specialty, Neurology Specialty, Cardiology Specialty, Other Specialties); Delivery Mode (Web / Cloud Based Delivery Mode, On-Premise Delivery Mode)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 34 Featured) -

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â